VKTX

Viking Therapeutics, Inc.

50.61 USD
-0.03 (-0.06%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Viking Therapeutics, Inc. stock is down -25.04% since 30 days ago. The next earnings date is Jul 24, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
17 Jun 19:44 17 Jan, 2025 25.00 CALL 21 690
17 Jun 19:44 16 Jan, 2026 50.00 PUT 28 103
18 Jun 13:53 19 Jul, 2024 70.00 CALL 200 1779
18 Jun 14:47 19 Jul, 2024 75.00 CALL 350 1085
18 Jun 15:32 20 Sep, 2024 70.00 CALL 180 4006
18 Jun 15:34 20 Sep, 2024 70.00 CALL 407 4006
18 Jun 17:01 21 Jun, 2024 55.00 PUT 75 1550
18 Jun 17:01 17 Jan, 2025 50.00 CALL 28 415
18 Jun 17:40 19 Jul, 2024 55.00 CALL 100 412
18 Jun 19:43 21 Jun, 2024 55.00 PUT 75 1550

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

  • Truist Securities
    Mon Jun 17, 11:28
    buy
    confirm
  • Raymond James
    Tue Jun 4, 14:09
    buy
    confirm
  • Maxim Group
    Tue Jun 4, 14:02
    buy
    confirm
  • HC Wainwright & Co.
    Tue Jun 4, 10:00
    buy
    confirm